eli lilly gip glp-1 Lilly's Investigational Dual and Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes Eli Lilly's experimental weight-loss drug
Description
It needs to be administered with care though
Fox River MedSpa offers personalized guidance for healthier living.
Diabetes mellitus is a major risk factor for both cardiovascular and chronic kidney disease (CKD) while CKD is also associated with cardiovascular morbidity
Recently, agonists of glucagon-like peptide-1 (GLP-1) receptor, designed based on the gut hormone GLP-1, have been developed as anti-obesity drugs and have demonstrated remarkable efficacy in treating both obesity and diabetes
Retrospective data showed that GLP-1 receptor agonist use was associated with a 51% reduction in colorectal cancer odds among patients with inflammatory bowel disease.
